The implementation of biomarkers into clinical practice is an exciting area of research, and the field of non-small cell lung cancer (NSCLC) is no exception to this. In this interview, Alastair Greystoke, PhD, of the University of Newcastle & Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK , discusses both PD-L1 expression and tumor mutational burden (TMB) as biomarkers in NSCLC, highlighting the importance of both factors. Dr Greystoke speculates the future use of blood tests to assess both circulating tumor cells and free DNA, and the use of TMB assays in determining what the efficacy of immunotherapy is likely to be. Briefly explored are novel pharmaceuticals for small cell lung cancer, including Rova-T, an experimental antibody targeting DLL3. This video was recorded at the UK Oncology Forum (OF) 2018, held in Liverpool, UK.